Immunoassay News and Research

RSS

Study explores immune escape mutations caused by prolonged viral shedding in immunocompromised COVID-19 patient

A new study examined a unique case of extended viral shedding in an immunocompromised patient that produced a series of SARS-CoV-2 immune escape mutations over a seven-month period.

8 Mar 2022

Aldosterone levels undetectably low in hospitalized COVID-19 patients

A new study reports finds very low aldosterone levels in a subset of COVID-19 patients.

6 Mar 2022

Declining immune responses against SARS-CoV-2 variants in dialysis patients post-vaccination

Researchers examined systemic B and T cell responses 16 weeks after BNT162b2 vaccination, and the potency of vaccine-induce neutralizing antibodies, in hemodialysis patients and healthcare workers with no comorbidities.

25 Feb 2022

Memory B cells induced by mRNA vaccine may help generate antibodies against Omicron

In a recent research article published in the journal of Science Immunology, a team of researchers from Japan performed longitudinal analysis on the cellular composition of receptor-binding domain (RBD) memory B cell subsets and its antibody binding and neutralizing activity against the Beta, Delta, and Omicron variants following the second dose of a messenger ribonucleic acid (mRNA) vaccine.

8 Feb 2022

Novel, rapid and efficient assay for SARS-CoV-2 neutralizing antibodies

Researchers validate a quick, highly efficient, and automated assay to detect neutralizing antibodies against SARS-CoV-2.

7 Feb 2022

Researchers explore natural SARS-CoV-2 infection in pet rabbits in France

In a new study, researchers reported the first evidence of natural SARS-CoV-2 infections among domestic rabbits in France.

1 Feb 2022

Study assesses anti-SARS-CoV-2 antibody response to mRNA-1273 vaccination over time

A new study has assessed the antibody responses to the mRNA-1273 Moderna vaccine over time.

31 Jan 2022

Study shows homologous COVID boosters better than heterologous in most kidney transplant recipients

Researchers screen kidney transplant recipients to evaluate their serological responses following immunization with three doses of the COVID-19 vaccine.

30 Jan 2022

Alterations of sphingolipids and their metabolizing enzymes in hospitalized or convalescent COVID-19 patients

An interdisciplinary team of researchers from Europe analyzed the alterations of sphingolipids and their metabolizing enzymes in hospitalized or convalescent COVID-19 patients.

26 Jan 2022

Seroepidemiologic surveys for assessment of the COVID-19 pandemic in Japan

In a new study, a team of researchers demonstrated that Japan had witnessed a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Delta variant-induced endemic between August and December 2021.

17 Jan 2022

Specific immunoresponse to SARS-CoV-2 in cats and dogs housed with COVID-19 patients

Researchers conducted a detailed epitope mapping of Np and developed an experimental double antigen-based ELISA.

13 Jan 2022

The Native Antigen Company Expands Range of Norovirus-Like Particles

The Native Antigen Company today announced the expansion of its norovirus-like particle range, with the addition of six new reagents.

From The Native Antigen Company 13 Jan 2022

Cellular and humoral response to SARS-CoV-2 in multiple sclerosis patients using disease-modifying therapies

Researchers examine the effects of disease-modifying therapies implemented for treating multiple sclerosis on the immune response to SARS-CoV-2 infection.

12 Jan 2022

Booster mRNA vaccination effective in reviving anti-SARS-CoV-2 antibody titers among the elderly

A new study found that a booster dose vaccination against COVID-19 was successful in taking binding. and neutralizing antibodies to levels higher than those observed after the initial double-dose regimen.

7 Jan 2022

Antibody binding response significantly reduced for Omicron compared to other SARS-CoV-2 variants

Researchers analyzed ACE2-binding inhibition and antibody binding for the SARS-CoV-2 Omicron variants in individuals with varying levels of immunity.

6 Jan 2022

Booster dose elicits cross-reactive humoral immunity against SARS-CoV-2 Delta and Omicron variants

Researchers determine the cross-reactivity of the SARS-CoV-2 spike glycoprotein-induced antibodies before and after a third SARS-CoV-2 vaccine dose.

5 Jan 2022

NAbs activity against SARS-CoV-2 variants, including Omicron, in an elderly vaccinated cohort

Researchers investigate the neutralizing antibody activity against different variants of SARS-CoV-2 in fully immunized elderly individuals.

3 Jan 2022

TriSb92 as a potential inhibitor against SARS-CoV-2 variants including Omicron

New findings indicate that TriSb92 is a potent inhibitor of SARS-CoV-2 infection targeting a conserved site in the RBD of the spike, which is insensitive for immune escape mutations found in the relevant variants of concern, including Omicron

31 Dec 2021

Pre-existing immunity against influenza can lower SARS-CoV-2 infection burden and spread

A recent study by a team of European researchers demonstrated how antibodies induced by currently circulating influenza A H1N1 strains can cross-react with the important part of the SARS-CoV-2 spike glycoprotein that interacts with the human cell receptor. Their paper is currently available on the medRxiv* preprint server while it undergoes peer review.

28 Dec 2021

Extended interval between second and third vaccination beneficial against SARS-CoV-2 Omicron variant

A new study proposes a multi-boost vaccine strategy with a longer duration between the second and third dose, as that would be beneficial in acquiring immunity against severely mutated SARS-CoV-2 variants.

22 Dec 2021